---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087273"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:56:44.268676+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Natera Q2 revenue up 58% to $413.4M, loss narrows to $37.5M, guides higher

## Summary
- Revenue $413.4M (+58.1% YoY); product revenue $411.4M (+59.3%); gross margin 58.8% vs 45.2%.
- Net loss $37.5M ($0.30 loss per share) vs $110.8M ($0.97) YoY; operating loss $43.9M vs $112.4M.
- Processed ~760,300 tests (+23.2%); oncology tests up 50.2% to ~125,400.
- Achieved positive cash flow ~$3.3M; FY 2024 revenue guidance raised to $1.49-$1.52B.
- Cash and investments $887.1M; outstanding debt $364.0M as of June 30, 2024.

## SEC filing metadata
- accession: 0001104659-24-087273
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465924087273/0001104659-24-087273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465924087273/tm2420614d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087273
- JSON: https://secwatch.observer/filing/0001104659-24-087273.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.